VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Flynn on CDK Inhibitors for the Treatment of CLL

Joseph M. Flynn, DO
Published: Monday, Apr 07, 2014

Joseph M. Flynn, DO, MPH, FACP, co-director, Division of Hematology, associate physician-in-chief, OSUCCC - James, discusses cyclin-dependent kinase (CDK) inhibitors for the treatment of chronic lymphocytic leukemia (CLL).

Most CDK inhibitors have been looked at in both solid and liquid tumors, Flynn says. CDK inhibitors have been looked at in CLL because it is preferable to treat the disease with an agent that has a low toxicity profile​.

CDK inhibitors have an interesting history in CLL. Alvocidib (flavopiridol) was looked at first, but did not demonstrate much activity. Nevertheless, alvocidib opened the door for other CDK inhibitors in this disease, like dinaciclib.
 

<<< View more from the 2014 AACR Annual Meeting

Joseph M. Flynn, DO, MPH, FACP, co-director, Division of Hematology, associate physician-in-chief, OSUCCC - James, discusses cyclin-dependent kinase (CDK) inhibitors for the treatment of chronic lymphocytic leukemia (CLL).

Most CDK inhibitors have been looked at in both solid and liquid tumors, Flynn says. CDK inhibitors have been looked at in CLL because it is preferable to treat the disease with an agent that has a low toxicity profile​.

CDK inhibitors have an interesting history in CLL. Alvocidib (flavopiridol) was looked at first, but did not demonstrate much activity. Nevertheless, alvocidib opened the door for other CDK inhibitors in this disease, like dinaciclib.
 

<<< View more from the 2014 AACR Annual Meeting


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x